(Q43102413)

13 November 2017

Evidence for using nebulised antibiotics in cystic fibrosis (English)

1 reference

13 November 2017

0 references

0 references

Conway SP

1

1 reference

PMCID

1717877

13 November 2017

language of work or name

English

0 references

publication date

1 April 1999

1 reference

Archives of Disease in Childhood

13 November 2017

1 reference

13 November 2017

80

1 reference

13 November 2017

4

1 reference

13 November 2017

307-309

1 reference

Urinary N-acetyl-beta-D-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation

13 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1717877

Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1717877

Compliance with treatment in adult patients with cystic fibrosis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1717877

Treatment compliance in adults with cystic fibrosis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1717877

Inhaled antibiotics in cystic fibrosis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1717877

Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1717877

Quantitative deposition of aerosolized gentamicin in cystic fibrosis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1717877

Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1717877

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1717877

Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1717877

Nebulized gentamicin in children and adolescents with cystic fibrosis.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1717877

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1717877

A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1717877

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1717877

Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis

15 August 2018

1 reference

12 December 2020

Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis

1 reference

12 December 2020

Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum

1 reference

12 December 2020

Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

1 reference

12 December 2020

Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa

1 reference

12 December 2020

Long-term tobramycin aerosol therapy in cystic fibrosis

1 reference

12 December 2020

Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis

1 reference

12 December 2020

Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone

1 reference

12 December 2020

Lung distribution and pharmacokinetics of aerosolized tobramycin

1 reference

12 December 2020

Assessment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis

1 reference

12 December 2020

Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum

1 reference

12 December 2020

Identifiers

DOI

10.1136/ADC.80.4.307

1 reference

13 November 2017

1 reference

13 November 2017

1 reference

PMCID

1717877